Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response

A point mutation in the BRAF gene, leading to a constitutively active form of the protein, is present in 45%–60% of patients and acts as a key driver in melanoma. Shortly after therapy induction, resistance to MAPK pathway-specific inhibitors develops, indicating that pathway inhibition is circumven...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Mathias Bernhardt, Daniel Novak, Yassen Assenov, Elias Orouji, Nathalie Knappe, Kasia Weina, Maike Reith, Lionel Larribere, Christoffer Gebhardt, Christoph Plass, Viktor Umansky, Jochen Utikal
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2017-05-01
Serier:	Stem Cell Reports
Fag:	melanoma reprogramming BRAF therapy resistance iPSC iPCC cancer stem cells induced pluripotency inhibitor
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2213671117301133
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!